miRNA-21 may serve as a promising noninvasive marker of glioma with a high diagnostic performance: a pooled analysis of 997 patients

Xinli Zhao*, Zhihong Xiao*, Bin Li, Hongwei Li, Bo Yang, Tian Li and Zubing Mei

Abstract

Background: Although various serum and tissue biomarkers have been investigated for glioma diagnosis, no gold standard has been identified. miRNA-21 was demonstrated to be a promising biomarker for the diagnosis of various brain tumors, whereas there remains uncertainty concerning whether miRNA-21 could be used as a good clinical diagnostic biomarker for glioma. The current meta-analysis aimed to evaluate the diagnostic accuracy of miRNA-21 as a potent biomarker in adults with suspected glioma.

Methods: The Pubmed and Embase databases were searched systematically from inception to January 2020 to identify relevant research reports. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were calculated. Summary receiver operating characteristic (SROC) curves were used to evaluate the overall diagnostic performance. Meta-regression and subgroup analyses were conducted to determine the source of heterogeneity and test the robustness of the results.

Results: From 5394 citations with 997 subjects that met the inclusion criteria, 11 studies were selected. Summary estimates of the diagnostic performance of miRNA-21 were as follows: sensitivity, 0.83 [95% confidence interval (CI): 0.73–0.89]; specificity, 0.92 [95% CI: 0.85–0.96]; PLR, 10.20 [95% CI: 5.10–20.30]; NLR, 0.19 [95% CI: 0.12–0.31]; and DOR, 54 [95% CI: 19–155]. The area under the SROC curve was 0.94 [95% CI: 0.92–0.96]. Deeks’s funnel plot revealed no evidence of publication bias (p = 0.59). Meta-regression analysis suggested that study publication year could contribute to the heterogeneity. Subgroup analysis found miRNA-21 had a constant high diagnostic accuracy across different ethnicity, glioma grade, sample source, and study region.

Conclusion: This meta-analysis demonstrated that miRNA-21 has high diagnostic performance and could serve as a promising noninvasive diagnostic marker for glioma. Further large prospective studies are needed to validate its diagnostic value and its prognostic significance and therapeutic effects.

Keywords: brain tumors, diagnostic accuracy, glioma, meta-analysis, miRNA-21

Received: 18 July 2020, revised manuscript accepted: 17 December 2020.
Brain tumors are characterized by high morbidity and mortality owing to their localization and often locally invasive growth. Glioma, accounting for the majority of brain-cancer-related deaths, are primary brain tumors that are thought to derive from neuroglial stem or progenitor cells. Although surgery, radiotherapy, and alkylating agent chemotherapy are still the mainstay therapies, and all are applied in clinical treatment, the diagnosis and treatment of brain tumors, especially glioma, are the primary challenge for future neurologists, neurosurgeons, and oncologists. Therefore, there is an urgent need to explore novel molecular targets for better diagnosis of glioma.

MicroRNAs (miRNAs) are a class of small noncoding single-stranded RNA molecules that regulate RNA silencing and expression of certain genes. They also play significant roles as oncogenes/tumor suppressors in various kinds of tumors. At the post-transcriptional level, miRNAs can regulate the expression of target genes by binding to their 3′-untranslated regions (3′-UTR) to participate in the regulation of life activities such as individual development, apoptosis, proliferation, and differentiation. Accumulating evidence also demonstrates miRNAs are expressed abnormally in a series of diseases, especially in various tumors. Indeed, there are a large number of literature reports that miRNAs can serve as reliable biomarkers for the diagnosis and prognosis of human gliomas.

miRNA-21 is one of the most studied types of miRNA. Previous studies have found that miRNA-21 is highly expressed in diverse cancer types and may serve as a biomarker for tumor diagnosis and prognosis. miRNA-21 is found not only in tissues, but also in a wide variety of extracellular fluid including cerebrospinal fluid (CSF), serum, plasma, saliva, and gastrointestinal fluids. Although numerous studies have proposed the diagnostic value of miRNA-21 in gliomas, results have been variable and inconclusive. The main purpose of this study was to investigate the diagnostic accuracy of miRNA-21 for detecting glioma, with the aim of determining whether miRNA-21 could be considered for use in screening patients with suspected glioma.

**Methods**

**Protocol**

This study was conducted following the Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies (PRISMA-DTA) guidelines (see Supplemental Table S1) and Assessing the methodological quality of systematic reviews (AMSTAR) Guidelines. Neither ethics approval nor patient consent was required for this manuscript.

**Search strategy**

Before searching the literature, two reviewers (XZ and BL or ZM) searched the Cochrane Collaboration, PROSPERO, Joanna Briggs Institute (JBI), and INPLASY databases to avoid duplication. We then searched PubMed and Embase from inception to January 2020 using medical subject headings (MeSH), Emtree, and text word with no language limitations. Taking PubMed as an example, we combined the Medical Subject Heading (MeSH) terms and free-text words to implement search strategies including: (microRNA OR miRNA OR miR) AND (glioma* OR glioblastoma*) AND (“Sensitivity and Specificity” OR “diagnostic accuracy” OR “Predictive Value of Tests” OR “negative predictive value” OR “false positive” OR “false positive” OR “positive predictive value” OR “diagnostic accuracy”). Detailed search strategies are available in Supplemental Appendix 1. The literature search was also supplemented by a combined manual search in the reference lists from the related articles, reviews, and meta-analyses.

Two investigators (ZM and BL) independently and in duplicate carried out the initial research, importing the literature to EndNote X9.1 (Clarivate Analytics, Philadelphia, PA, USA), deleting duplicate records, excluding irrelevant literature, screening titles/abstracts, and enrolling studies with detailed classification. Eligibility was based on full text and supplement materials. Any inconsistencies were forwarded to a third reviewer (BY or TL) for a final decision.

**Eligibility criteria**

Included studies were required to meet all of the following criteria: (a) studies used the gold reference standard (histopathological examinations) to make definite diagnosis of brain tumors; (b) studies providing the diagnostic performance of miRNA-21 in blood (serum or plasma), tissue, and CSF for gliomas including World Health Organization (WHO) grade I–IV gliomas; (c) studies providing sufficient data for constructing the 2×2 contingency tables with true positive
(TP), false positive (FP), true negative (TN), and false negative (FN) available.

Studies were excluded if they met one of the following criteria: (a) studies had insufficient data to yield diagnostic accuracy; (b) studies published in the form of letters, comments, reviews, or meta-analyses without original data; (c) studies belonging to basic research; (d) articles without peer-review or unpublished; (e) studies that were published repeatedly or had qualitative outcomes. Two independent authors assessed all of the studies for inclusion and exclusion. Any disagreements were discussed and resolved by consensus and involvement of a senior author if necessary.

Data extraction
Data from all included studies were abstracted independently by two authors using a standardized data collection form to address population features, reference standard, assay characteristics, methodological quality, study design, and diagnostic data, including study author, publication year, patient ethnicity and country, the number of cases and controls, glioma type or World Health Organization (WHO) grade, sample source, with or without reference gene, study design, and miRNA profiling, which were summarized in a standardized Excel (Microsoft Corporation, Redmond, WA, USA). All outcomes are dichotomous variables, including TP, FP, TN, and FN.

Cohen’s kappa coefficient
Cohen’s kappa coefficient (κ) – a statistical measure that permits investigation into study characteristics – was utilized to measure the inter-rater agreement of enrolled studies; Cohen’s κ measures the agreement between two raters who each classify N items into C mutually exclusive categories.

Risk of bias assessment
The risk of bias for the included studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. The categories in the scoring system used for assessing risk of bias consisted of patient selection, index test, reference standard, flow, and timing. An answer of Yes, No, or Unclear was allocated to each assessed study. Only Yes answers were given a score. Risk of bias was performed independently by two authors and cross checked.

Statistical analysis
All meta-analyses were performed using the “Midas” module in the STATA 15.0 (Stata Corp LP, College Station, TX, USA). The summary sensitivity, specificity and receiver operating characteristic (SROC) curves were calculated and forest plots were generated to test diagnostic accuracy using the bivariate logistic regression model and hierarchical SROC model. In addition, a hierarchical SROC curve with a 95% prediction and confidence contours was plotted to present the results graphically. Spearman correlation test was used to assess the threshold effect. If no threshold effect was examined, the bivariate random-effect model was applied to conduct the meta-analysis. The I² statistic was calculated to assess inter-study heterogeneity. According to the Cochrane handbook, an I² statistic >50% was considered significant heterogeneity between studies. Subgroup analysis was carried out to investigate the potential influential factors on the summary sensitivity and specificity, which included geographical area (US versus Europe versus Asia), study design (prospective studies versus retrospective studies), ethnicity (Caucasian versus Asian), publication year (before 2015 versus 2015 and after), glioma grade [mixed grade (WHO I/II–IV) versus WHO IV (glioblastoma) versus low grade (grade I–II) versus high grade (grade III–IV)], sample source (CSF versus blood versus tissue), sample size (<50 versus ≥50), reference gene applied or not (yes versus no), miRNA profiling (simple versus multiple), and QUADAS-2 (high risk versus low risk). Deeks’ funnel plot was used to examine the possibility of publication bias with a p value <0.1 indicating existence of publication bias. Fagan’s nomogram was also used to calculate pre-test probability and post-test probability to assess the diagnostic power of miRNA-21 in clinical practice.

Results

Literature search
The initial database search yielded 3168 citations after removing duplicates. Of these, 3143 irrelevant citations were removed after reviewing titles and abstracts, leaving 25 relevant studies for further consideration. We excluded another 14 articles after full-text reading based on the exclusion criteria (six without sufficient data for generating 2×2 contingency table; four letters, comments, reviews, or meta-analyses; two basic research
studies; and two non-glioma brain tumors). Finally, 11 studies met the inclusion criteria and were retained in the meta-analysis (Figure 1). Cohen’s κ to measure the inter-rater agreement of enrolled studies was 0.85, indicating a favorable agreement.

**Study characteristics**
Baseline characteristics of the 11 included studies are displayed in Table 1. In summary, 11 studies with 19 sets of data enrolling 997 patients published between 2012 and 2017 were included in the meta-analysis. Four studies were conducted in Europe, two in the US, and five in Asia. Two studies had a prospective design, and the remaining nine studies had a retrospective design. In terms of ethnicity, six studies were conducted in Caucasian populations and five in Asian populations. The most common glioma investigated were mixed grade gliomas (WHO I/II–IV) in seven studies and WHO IV (glioblastoma) in five studies. Seven studies used CSF as samples, five used blood, and one used tissue. Seven studies were rated as high risk of bias and the other four were rated as low risk based on QUADAS-2.

**Threshold effect**
Spearman correlation coefficient of sensitivity and 1-specificity yielded −0.12 (p = 0.43), indicating no heterogeneity resulting from threshold effect.

**Diagnostic performance**
We used random effects model to estimate overall performance of miRNA-21 for diagnosis of glioma. Meta-analysis found that the summary sensitivity and specificity combining all included studies were 0.83 [95% confidence interval (CI): 0.73–0.89] and 0.92 (95% CI: 0.85–0.96), respectively (Figure 2). Significant inter-study heterogeneity was noted according

---

**Figure 1.** Flow diagram of literature research.
### Table 1. Baseline features of included studies.

| Author         | Year | Ethnicity | Country | Case | Control | Glioma type or WHO grade | Sample source | With reference gene | Study design | miRNA profiling | QUADAS-2 |
|----------------|------|-----------|---------|------|---------|---------------------------|---------------|---------------------|--------------|-----------------|----------|
| Baraniskin et al. | 2012 | Caucasian | Germany | 9    | 2       | Glioma                    | CSF           | No                  | Retrospective | Single assay    | 5        |
| Teplyuk et al.  | 2012 | Caucasian | Germany | 19   | 15      | Glioblastoma              | CSF           | Yes                 | Retrospective | Single assay    | 6        |
| Wang et al.     | 2012 | Asian     | China   | 10   | 10      | Glioblastoma              | Plasma        | Yes                 | Retrospective | Single assay    | 4        |
| Wang et al.     | 2012 | Asian     | China   | 30   | 10      | Glioma [WHO grade II–IV]  | Plasma        | Yes                 | Retrospective | Single assay    | 4        |
| Akers et al.    | 2013 | Caucasian | US      | 13   | 14      | Glioblastoma              | CSF           | No                  | Prospective   | Single assay    | 5        |
| Akers et al.    | 2013 | Caucasian | US      | 15   | 14      | Glioblastoma              | CSF           | No                  | Prospective   | Single assay    | 5        |
| Yuan et al.     | 2014 | Asian     | China   | 20   | 20      | Glioma [WHO grade II–IV]  | CSF           | No                  | Retrospective | Multiple assay   | 4        |
| Zhao et al.     | 2014 | Asian     | China   | 52   | 43      | Glioma [WHO grade II–IV]  | Plasma        | Yes                 | Retrospective | Single assay    | 5        |
| Shi et al.      | 2015 | Asian     | China   | 70   | 25      | Glioma [WHO grade II–IV]  | CSF           | Yes                 | Retrospective | Single assay    | 6        |
| Shi et al.      | 2015 | Asian     | China   | 50   | 25      | Glioma [WHO grade II–IV]  | Serum         | Yes                 | Retrospective | Single assay    | 6        |
| D’Urso et al.   | 2015 | Caucasian | Italy   | 30   | 30      | Glioma [WHO grade II–IV]  | Plasma        | No                  | Retrospective | Multiple assay   | 5        |
| D’Urso et al.   | 2015 | Caucasian | Italy   | 30   | 82      | Glioma [WHO grade II–IV]  | Plasma        | No                  | Retrospective | Multiple assay   | 5        |
| Qu et al.       | 2016 | Asian     | China   | 35   | 10      | Glioma                    | Tissue        | Yes                 | Retrospective | Multiple assay   | 6        |
| Qu et al.       | 2016 | Asian     | China   | 35   | 10      | Glioma                    | CSF           | Yes                 | Retrospective | Multiple assay   | 6        |
| Akers et al.    | 2017 | Caucasian | US      | 10   | 12      | Glioblastoma              | CSF           | No                  | Prospective   | Multiple assay   | 5        |
| Akers et al.    | 2017 | Caucasian | US      | 18   | 20      | Glioblastoma              | CSF           | No                  | Prospective   | Multiple assay   | 5        |
| Santangelo et al.| 2017 | Caucasian | Italy   | 44   | 30      | Glioblastoma              | Serum         | Yes                 | Retrospective | Multiple assay   | 4        |
| Santangelo et al.| 2017 | Caucasian | Italy   | 60   | 30      | Glioma [high grade]       | Serum         | Yes                 | Retrospective | Multiple assay   | 4        |
| Santangelo et al.| 2017 | Caucasian | Italy   | 15   | 30      | Glioma [low grade]        | Serum         | Yes                 | Retrospective | Multiple assay   | 4        |

CSF, cerebrospinal fluid; GBM, glioblastoma multiforme; LG, low grade; HG, high grade; QUADAS, quality assessment of diagnostic accuracy studies; WHO, World Health Organization; US, United States.
to the Q test (sensitivity: $Q = 93.26, p < 0.001$; specificity: $Q = 60.26, p < 0.001$). The $I^2$ statistic also indicated substantial heterogeneity in terms of both sensitivity ($I^2 = 80.7\%$) and specificity ($I^2 = 70.1\%$). The summary diagnostic odds ratio (DOR) was 54 (95% CI: 19–155), suggesting the potential of a 54-fold higher level of miRNA-21 in subjects with positive glioma diagnosis compared with subjects with negative results, indicating a high diagnostic accuracy. The summary positive likelihood ratio (PLR) was 10.20 (95% CI: 5.10–20.30) and the summary negative likelihood ratio (NLR) was 0.19 (95% CI: 0.12–0.31). The area under the receiver operating characteristic (ROC) curve was 0.94 (95% CI, 0.92–0.96) (Figure 3). A Fagan nomogram was plotted to demonstrate the relations between pre-test and post-test probabilities and likelihood ratio (Figure 4). As noted in Figure 5, the summary PLR and NLR for miRNA-21 diagnosis of brain tumors were concentrated in the right lower quadrant, which indicated that PLR was <10 and NLR was >0.1.

**Figure 2.** Sensitivity and specificity of miRNA for diagnosis of gliomas. CSF, cerebrospinal fluid; GBM, glioblastoma multiforme; LG, low grade; HG, high grade; miRNA, microRNA.

**Figure 3.** SROC curve with 95% confidence contour and 95% prediction contour of miRNA-21 diagnostic value for gliomas. AUC, area under the curve; SENS, sensitivity; SPEC, specificity; SROC, summary receiver operating characteristic.
To further examine the potential sources of heterogeneity, we carried out a meta-regression analysis based on geographical area (US, Europe or Asia), study design (prospective studies or retrospective studies), ethnicity (Caucasian or Asian), publication year (before 2015 or 2015 and after), glioma grade [mixed grade (WHO I/II–IV) versus WHO IV (glioblastoma) versus low grade (WHO I–II) versus high grade (WHO III–IV)], sample source (cerebrospinal fluid, blood or tissue), sample size (<50 or ≥50), reference gene applied or not (yes or no), miRNA profiling (simple or multiple), and QUADAS-2 (high risk or low risk). In the present meta-analysis, we found a significant effect on sensitivity ($p = 0.03$) for covariate of reference gene, and we did not find other covariates included in the meta-regression analysis to be the potential source of heterogeneity (all $p > 0.05$) (Figure 6). Results of subgroup analysis based on the above variables were consistent with the primary analyses in terms of sensitivity and specificity (Table 2).

### Sensitivity analysis

Sensitivity analysis was conducted by removing the included studies one by one and analyzing the SROC curve. As is shown in Figure 7, the results...
remained unchanged, suggesting that this meta-analysis was stable.

**Publication bias analyses**

Publication bias was examined using Deeks’ funnel plot test and visual inspection of funnel plot asymmetry. The shape of the funnel plot of the pooled DOR of miRNA-21 for the diagnosis of glioma revealed generally symmetry (Figure 8). Deeks' asymmetry test also showed a statistically non-significant value ($p = 0.59$), further confirming no evident publication bias.

**Discussion**

**Principal findings**

This comprehensive review and meta-analysis is the first to explore the diagnostic value of miRNA-21 for glioma. Based on the findings of this study, we conclude that when miRNA is
applied to the diagnosis of glioma, the rate of missed diagnosis (17%) and misdiagnosis (8%) will be quite low. The pooled sensitivity and pooled specificity reach 0.83 (95% CI: 0.73–0.89) and 0.92 (95% CI: 0.85–0.96), respectively. And the diagnostic accuracy was high (DOR: 54, 95% CI: 19–155). This diagnostic accuracy was consistent when several subgroup analyses were performed (Table 2). In terms of these findings, miRNA-21, which can be detected in blood or CSF samples, has potential as a novel biological diagnostic tool for glioma.

Table 2. Subgroup analyses of the diagnostic accuracy of miRNA-21.

| Covariates                      | Subgroup          | n  | Sensitivity, % (95% CI) | p value | Specificity, % (95% CI) | p value |
|---------------------------------|-------------------|----|------------------------|---------|------------------------|---------|
| Geographical area               | US                | 2  | 73 (42–91)             | 0.77    | 91 (72–97)             | 0.88    |
|                                 | Europe            | 4  | 89 (74–95)             |         | 95 (70–99)             |         |
|                                 | Asia              | 5  | 80 (68–88)             |         | 92 (82–96)             |         |
| Study design                    | Prospective       | 2  | 73 (42–91)             | 0.30    | 91 (72–97)             | 0.96    |
|                                 | Retrospective     | 9  | 84 (75–90)             |         | 92 (84–97)             |         |
| Ethnicity                       | Caucasian         | 6  | 84 (69–92)             | 0.84    | 93 (79–98)             | 0.82    |
|                                 | Asian             | 5  | 80 (68–88)             |         | 92 (82–96)             |         |
| Publication year                | Before 2015       | 6  | 88 (75–95)             | 0.21    | 94 (86–98)             | 0.24    |
|                                 | 2015 and after    | 5  | 78 (65–87)             |         | 90 (78–96)             |         |
| WHO grade                       | Mixed grade (1/2–4)| 7  | 80 (75–84)             | 0.58    | 94 (90–96)             | 0.54    |
|                                 | IV (glioblastoma) | 5  | 76 (57–88)             |         | 88 (75–94)             |         |
|                                 | Low grade (1–2)   | 1  | 73 (45–92)             |         | 77 (58–90)             |         |
|                                 | High grade (3–4)  | 1  | 82 (70–90)             |         | 77 (58–90)             |         |
| Sample source                   | CSF               | 7  | 77 (62–88)             | 0.86    | 91 (83–96)             | 0.31    |
|                                 | Blood             | 5  | 88 (76–94)             |         | 93 (80–98)             |         |
|                                 | Tissue            | 1  | 60 (42–78)             |         | 80 (55–100)            |         |
| Sample size                     | <50               | 6  | 81 (66–91)             | 0.58    | 89 (81–94)             | 0.96    |
|                                 | ≥50               | 5  | 84 (73–91)             |         | 94 (76–99)             |         |
| Reference gene applied or not   | Yes               | 5  | 89 (69–97)             | 0.35    | 98 (87–100)            | 0.03*   |
|                                 | No                | 6  | 77 (69–84)             |         | 84 (77–89)             |         |
| miRNA profiling                 | Single            | 6  | 78 (73–83)             | 0.63    | 89 (84–94)             | 0.56    |
|                                 | Multiple          | 5  | 78 (73–82)             |         | 89 (85–92)             |         |
| QUADAS-2                        | High risk         | 7  | 87 (75–93)             | 0.18    | 93 (85–97)             | 0.63    |
|                                 | Low risk          | 4  | 71 (64–77)             |         | 85 (76–92)             |         |

*p < 0.1
CI, confidence interval; CSF, cerebrospinal fluid; miRNA, microRNA; QUADAS, quality assessment of diagnostic accuracy studies; WHO, World Health Organization; US, United States.
Interpretation

Although histological diagnosis remains the gold standard for glioma, due to a type of highly heterogeneous tumors arising from brain parenchyma, molecular diagnostic markers such as isocitrate dehydrogenase (IDH) mutation status, chromosome 1p/19q status, copy number alterations of chromosome 7 and 10 and of telomerase reverse transcriptase (TERT) promoter, BRAF, and H3F3A mutations are of limited diagnostic value. Therefore, more and more studies began to focus on the integration of molecular aspects when diagnosing and managing gliomas, which included the use of miRNAs as diagnostic markers.40,46–48

Through bioinformatics analysis, it has been found that related miRNAs play a regulatory role in a variety of tumors, including CNS tumors. Previous studies have identified specific miRNAs associated with the diagnosis of gliomas. Recently, it has been confirmed that five combined miRNAs are involved in the alterations of MGMT, and that TP53 and is related to the progression of glioblastoma.49 Among these miRNAs, miRNA-21 and miRNA-181d have been found to play a regulatory role in the carcinogenesis of glioblastoma, while miRNA-144 and miRNA-29a are related to the progression of glioblastoma. Although the diagnostic value of miRNA in glioma has been published in many different studies, further validation studies and comprehensive meta-analyses are needed with large cohort sample sizes to confirm the diagnostic performance of specific miRNA in glioma.

Imaging examinations such as magnetic resonance imaging (MRI) or positron emission tomography (PET) imaging are the first choice for the diagnosis of gliomas, but because of cost and low availability, they are not widely used, leading to delays in diagnosis. Therefore, there is an urgent need for a diagnostic method that is efficient, fast, and cost-effective. Blood and CSF samples are easier to obtain from patients and can be used to measure circulating miRNAs. Multiple studies have shown that various miRNAs (especially miRNA-21) in plasma and CSF of GBM patients are elevated significantly.

A study conducted by Santangelo et al. found that plasma exosomal miRNA had high sensitivity
(0.81) and specificity (0.77) to high-level glioma, while high sensitivity was found at low-level glioma (0.75), low specificity (0.47). A study by Qu et al. found that the CSF miRNA has both high sensitivity (0.88) and specificity (0.89) for the diagnosis of glioma. Therefore, an updated and comprehensive synthesis of the evidence on the accuracy of miRNA-21 is warranted.

Moreover, blood or CSF sample measurement is convenient and less invasive, and qRT-PCR analysis techniques are already available in most routine laboratories. In addition, the results are readily interpretable by clinicians. Finally, this technique does not consume samples needed for other tests. Given the evidence from our findings, miRNA-21 has high sensitivity (0.83, 95% CI 0.73–0.89) and specificity (0.92, 95% CI 0.85–0.96) for the diagnosis of glioma, and the results are consistent in different WHO grades and other subgroups. Previous meta-analysis for the diagnostic accuracy of extracellular miRNA-21 for gliomas demonstrated an AUC of 0.94 in brain tumor and 0.95 in glioma, which is in line with values found from our study. The results of meta-regression analysis demonstrated that the reference gene was a potentially significant factor influencing clinical heterogeneity in our study. Nevertheless, we cannot exclude the influence of some of the unmeasured causes of heterogeneity. Some other factors, such as patient-related factors including ethnicity, sample source, and tumor type, could also influence the results. Although significantly different effects were not found among subgroups, these factors should not be neglected due to the small sample size analyzed. The results, therefore, need to be interpreted with caution. The key findings of this study that were not observed in other similar studies lie in the fact that the diagnostic value of miRNA-21 was further validated in different subgroups, especially in different glioma grades including low (grade I/II) and high grade (grade III/IV), glioblastoma (grade IV), and mixed grade.

Strength and limitations
To the best of our knowledge, this study represents the largest and most comprehensive study on the assessment of the diagnostic accuracy of miRNA-21 in gliomas. The results regarding the diagnostic value of miRNA-21 in our meta-analysis were generally consistent with those from
previous individual studies and systematic reviews, and further eligible studies were included and results were updated. Furthermore, we strictly followed the recent PRISMA-DTA guidelines for transparent and accuracy reporting to make research more credible and reproducible. One of important strengths of this study was that the retrieval strategy of this meta-analysis was formulated by a Cochrane Collaboration Member (TL). The strategy was thorough and specific, which aimed to enhance accuracy. McSH Terms, Emtree, and free text-words were used in PubMed and Embase. The retrieval results included a wide variety of publications from inception to 2020, especially publications in the past 3 years that had not been enrolled by other meta-analyses. The included literature was searched by two reviewers independently, evaluated by Cohen’s κ. And the final decisions on literature screening and selection were sent to the senior authors (TL and ZM) for final decision, which contributed to a well-controlled review. Secondly, we did not limit publication date during the search of the major databases, making it unlikely to miss important publications. At least two independent authors were involved in the study screening, data extraction, and risk of bias assessment, and data were then cross checked for accuracy. Finally, we selected a random-effects model to generate a more conservative estimate. Compared with the previous meta-analyses, the present one included more additional studies and more thorough analyses were carried out, finding that the diagnostic value of miRNA-21 remained across various glioma grades, ethnicities, and sample sources.

There are several limitations to the present study. First, we did not include conference abstracts, unpublished gray literature, and studies not written in English, which may result in certain forms of bias of our findings. Furthermore, we omitted studies not indexed in our searched databases (e.g., Pubmed and Embase). Nevertheless, Deeks’ funnel plot suggested the absence of publication bias that could have influenced our results. Second, moderate-to-significant heterogeneity was indicated, which was expected partially because the studies included used different samples to detect miRNA-21, involved glioma patients with different WHO grades, had different study design, and other cases. Although we had conducted meta-regression analysis based on several factors for sensitivity and specificity (Table 2), this could only partly determine the potential source of heterogeneity. Third, according to QUDAS-2 tool, we found that most of the included studies did not report the assessment of blinding method, which showed a high or unclear risk of bias. These methodological issues should be avoided in future study design of diagnostic studies. Finally, although our results further demonstrate the diagnostic value of miRNA-21 for gliomas, the findings of the current study were based on aggregated, not individual, patient level data, which precluded adjustments for confounding factors and limited further analysis in certain groups of patients. And more than 50% (6/11) of the included studies had fewer than 50 patients for analysis. The small sample size did not allow for further subgroup analyses, although the consistent results were indicated in several subgroup analyses. We propose that future large well-designed studies to enroll a larger population with more homogeneous characteristics should be conducted, although this may result in selection bias.

**Implications**

Compared with several imaging diagnostic approaches such as MRI and PET imaging (the reported diagnostic sensitivity and specificity of 0.68–0.92 and 0.77–0.95 for MRI, respectively; and 0.88–0.90 and 0.73–0.75 for PET, respectively), blood miRNAs are considered as powerful cancer biomarkers with radiation-free and high diagnostic accuracy in various tumors. The diagnostic sensitivity and specificity of miRNA-21 of our study yielded were 0.83 and 0.92, respectively, which was comparable with those of MRI and PET imaging.

The present study showed that miRNA-21 provided satisfactory diagnostic accuracy for glioma and can serve as a diagnostic marker comparable with conventional MRI and PET imaging, and which could complement the use of MRI and PET imaging. Whether the combined use of miRNA-21 and MRI or PET imaging can provide a more satisfactory diagnostic performance for the early diagnosis of glioma or not requires further investigation. Moreover, because glioma is a heterogeneous disease, it may not be possible for miRNA-21 to serve as a gold standard biomarker. However, due to the inherent limitations of small sample size observational studies, we consider that only when further large-scale prospective, multicenter studies have validated the definite diagnostic value of miRNA-21 can the clinical application of miRNA-21 in the diagnosis...
of gliomas be applied routinely. Although currently the detection of miRNA-21 in the blood or CSF is not a gold standard biomarker for the diagnosis of glioma, it can provide meaningful reference information for clinicians that is not inferior to conventional MRI and PET imaging, while being more convenient and less expensive.

Conclusion

In conclusion, this meta-analysis indicates that miRNA-21 may be accurate enough to diagnose glioma. Subgroup analysis found miRNA-21 had a constant high diagnostic accuracy across different ethnicities, WHO grades, sample sources, and study regions. Although further large sample clinical studies are needed to establish the optimal approach to the application of miR-21, our evidence-based results clearly recommend, at least in part, the diagnostic value of miR-21 in glioma. Further large prospective studies are needed to validate its diagnostic value, its prognostic significance, and therapeutic effects.

Author contributions

Study concept and design (Bo Yang and Zubing Mei);

Acquisition of data (Xinli Zhao, Hongwei Li, Bin Li and Zubing Mei);

Analysis and interpretation of data (Xinli Zhao, Zhihong Xiao, Bo Yang, Bin Li and Zubing Mei);

Drafting of the manuscript (Xinli Zhao, Zubing Mei, Zhihong Xiao and Tian Li);

Critical revision of the manuscript for important intellectual content (all authors);

Study supervision (Bo Yang and Zubing Mei).

Conflict of interest statement

The authors declare that there is no conflict of interest.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Natural Science Foundation of China (grant no. 81774112) (to Z.M.) (grant no. 81401834) (to Z.X.), a grant from Siming Scholars from Shuguang Hospital (grant no. SGXZ-201913) (to ZM) and Health and Family Planning Commission Program of Wuhan City (grant no. WX18C29) (to Z.X.).

ORCID iD

Zubing Mei https://orcid.org/0000-0001-6823-7205

Data availability

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Supplemental material

Supplemental material for this article is available online.

References

1. Nabors LB, Portnow J, Ammirati M, et al. NCCN guidelines insights: central nervous system cancers, version 1.2017. J Natl Compr Cancer Netw 2017; 15: 1331–1345.

2. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.

3. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.

4. Ludwig K and Kornblum HI. Molecular markers in glioma. J Neurooncol 2017; 134: 505–512.

5. Weller M, Wick W, Aldape K, et al. Glioma. Nat Rev Dis Primers 2015; 1: 15017.

6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–297.

7. Yoo JK, Lee JM, Kang SH, et al. The novel microRNA hsa-miR-CHA1 regulates cell proliferation and apoptosis in human lung cancer by targeting XIAP. Lung Cancer 2019; 132: 99–106.

8. Lei L, Zhao X, Liu S, et al. MicroRNA-3607 inhibits the tumorigenesis of colorectal cancer by targeting DDI2 and regulating the DNA damage repair pathway. Apoptosis 2019; 24: 662–672.

9. Kurimoto R, Tsutsumi H, Uchida Y, et al. New regulatory mechanism of tumor suppressor microRNA let-7s (comprehensive approach for tumor suppressors in vitro). Ann Oncol 2019; 30: vi134.

10. Mohr AM and Mott JL. Overview of microRNA biology. Semin Liver Dis 2015; 35: 3–11.

11. Chen L, Yang J, Lü J, et al. Identification of aberrant circulating miRNA s in Parkinson's
disease plasma samples. Brain Behav 2018; 8: e00941.

12. Cai P, Li H, Huo W, et al. Aberrant expression of LncRNA-MIR31HG regulates cell migration and proliferation by affecting miR-31 and miR-31* in Hirschsprung’s disease. J Cell Biochem 2018; 119: 8195–8203.

13. Lai YC, Ushio N, Rahman M, et al. Aberrant expression of microRNAs and the miR-1/MET pathway in canine hepatocellular carcinoma. Vet Comp Oncol 2018; 16: 288–296.

14. Ma C, Nguyen HP, Luwor RB, et al. A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker. PLoS One 2018; 13: e0189452.

15. Tang Y, Zhao S, Wang J, et al. Plasma miR-122 as a potential diagnostic and prognostic indicator in human glioma. Neurology 2017; 38: 1087–1092.

16. Huang Q, Wang C, Hou Z, et al. Serum microRNA-376 family as diagnostic and prognostic markers in human gliomas. Cancer Biomark 2017; 19: 137–144.

17. Li C, Sun J, Xiang Q, et al. Prognostic role of microRNA-21 expression in gliomas: a meta-analysis. J Neurooncol 2016; 130: 11–17.

18. Si M, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene 2007; 26: 2799–2803.

19. Kanaan Z, Rai SN, Eichenberger MR, et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg 2012; 256: 544–551.

20. Liao Q, Han P, Huang Y, et al. Potential role of circulating microRNA-21 for hepatocellular carcinoma diagnosis: a meta-analysis. PLoS One 2015; 10: e0130677.

21. Wu L, Zheng K, Yan C, et al. Genome-wide study of salivary microRNAs as potential noninvasive biomarkers for detection of nasopharyngeal carcinoma. BMC Cancer 2019; 19: 843.

22. Pesta M, Kucera R, Topolcan O, et al. Plasma microRNA levels combined with CEA and CA19-9 in the follow-up of colorectal cancer patients. Cancers 2019; 11: 864.

23. Baraniskin A, Kuhnhen J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neurooncology 2012; 14: 29–33.

24. Ryu JK, Matthaei H, Dal Molin M, et al. Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. Pancreatology 2011; 11: 343–350.

25. Komatsu S, Ichikawa D, Takeshita H, et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 2011; 105: 104–111.

26. McNees MD, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA 2018; 319: 388–396.

27. Daly CH, Neupane B, Beyene J, et al. Empirical evaluation of SUCRA-based treatment ranks in network meta-analysis: quantifying robustness using Cohen’s kappa. BMJ Open 2019; 9: e024625.

28. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2015; 155: 529–536.

29. Reitsma JB, Glas AS, Rutjes AW, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005; 58: 982–990.

30. Rutter CM and Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 2001; 20: 2865–2884.

31. Higgins JP and Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–1558.

32. Deeks JJ, Macaskill P and Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58: 882–893.

33. Letter FT. Nomogram for Bayes theorem. N Engl J Med 1975; 293: 257.

34. Baraniskin A, Kuhnhen J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 2011; 117: 3140–3146.

35. Kopkova A, Sana J, Machackova T, et al. Aberrant expression of LncRNA-MIR31HG regulates cell migration and proliferation by affecting miR-31 and miR-31* in Hirschsprung’s disease. J Cell Biochem 2018; 119: 8195–8203.
38. D’Urso PI, D’Urso OF, Gianfreda CD, et al. miR-15b and miR-21 as circulating biomarkers for diagnosis of glioma. *Curr Genomics* 2015; 16: 304–311.

39. Qu K, Lin T, Pang Q, et al. Extracellular miRNA-21 as a novel biomarker in glioma: evidence from meta-analysis, clinical validation and experimental investigations. *Oncotarget* 2016; 7: 33994–34010.

40. Santangelo A, Imbruce P, Gardenghi B, et al. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. *J Neurooncol* 2018; 136: 51–62.

41. Shi R, Wang P-Y, Li X-Y, et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. *Oncotarget* 2015; 6: 26971.

42. Teplyuk NM, Mollenhauer B, Gabriely G, et al. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. *Neuromonology* 2012; 14: 689–700.

43. Wang Q, Li P, Li A, et al. Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. *J Exp Clin Cancer Res* 2012; 31: 97.

44. Yuan P, Xiaoying H and Xiaogang L. Identification of miR-128 and miR-21 in the cerebrospinal fluid as biomarker for the diagnosis of glioma. *Int J Lab Med* 2014; 18: 2464–2465, 2468.

45. Zhao B, Wu F, Zheng LF, et al. Expression and significance of plasma miR-21 in patients with glioma. *Prog Mod Biomed* 2014; 14: 2879–2881.

46. Azam Z, Quillien V, Wang G, et al. The potential diagnostic and prognostic role of extracellular vesicles in glioma: current status and future perspectives. *Acta Oncol* 2019; 58: 353–362.

47. Masui K, Cloughesy T and Mischel P. Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. *Neuropathol Appl Neurobiol* 2012; 38: 271–291.

48. Ohno M, Matsuzaki J, Kawauchi J, et al. Assessment of the diagnostic utility of serum microRNA classification in patients with diffuse glioma. *JAMA Netw Open* 2019; 2: e1916953.

49. Jesionek-Kupnicka D, Braun M, Trąbska-Kluch B, et al. MiR-21, miR-34a, miR-125b, miR-181d and miR-648 levels inversely correlate with MGMT and TP53 expression in primary glioblastoma patients. *Arch Med Sci* 2019; 15: 504–512.

50. Qu S, Guan J and Liu Y. Identification of microRNAs as novel biomarkers for glioma detection: a meta-analysis based on 11 articles. *J Neurol Sci* 2015; 348: 181–187.

51. Kopkova A, Sana J, Fadrus P, et al. Cerebrospinal fluid microRNAs as diagnostic biomarkers in brain tumors. *Clin Chem Lab Med* 2018; 56: 869–879.

52. Zhou Q, Liu J, Quan J, et al. MicroRNAs as potential biomarkers for the diagnosis of glioma: a systematic review and meta-analysis. *Cancer Sci* 2018; 109: 2651–2659.

53. Sterne JA, Gavaghan D and Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. *J Clin Epidemiol* 2000; 53: 1119–1129.

54. van Dijken BR, van Laar PJ, Holtman GA, et al. Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis. *Eur Radiol* 2017; 27: 4129–4144.

55. Xiao J, Jin Y, Nie J, et al. Diagnostic and grading accuracy of 18 F-FDOPA PET and PET/CT in patients with gliomas: a systematic review and meta-analysis. *BMC Cancer* 2019; 19: 767.

56. Wittmann J and Jäck H-M. Serum microRNAs as powerful cancer biomarkers. *Biochim Biophys Acta* 2010; 1806: 200–207.